Literature DB >> 26256007

Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study.

Benjamin Sneider1, Sofie Gry Pristed2, Christoph U Correll3, Jimmi Nielsen4.   

Abstract

Although evidence for efficacy of antipsychotic polypharmacy (APP) is sparse, APP is common in schizophrenia. The national Danish health registers were accessed to examine in schizophrenia patients: (1) cross-sectional prevalences of APP (1996-2012); (2) geographic variations in APP (2012); and (3) correlates of APP (2012). APP increased from 17.2% in 1996 to 30.8% in 2006 (p<0.001), declining to 24.6% in 2012 (p<0.001) (overall trend 1996-2012: α=0.653, 95% confidence interval (CI):0.327-0.979, p<0.001). Comparing the 1996-2005 and 2006-2012 cohorts APP occurred significantly faster in the 2006 cohort after schizophrenia diagnosis (p<0.0001). The predominant APP type changed from first-generation antipsychotic combinations in 1996 (77.3%) to first+second-generation antipsychotic combinations in 2003 (70.3%) and second-generation antipsychotic combinations in 2012 (59.2%). In 2012, the prevalence of APP varied from 19.4% in Copenhagen to 29.3% in the region of Zealand. Independent correlates of APP, explaining 37.9% of the variance, included a higher number of patients per psychiatrist (OR=1.04/10 patients, CI=1.03-1.06, p<0.001),lower proportion of males (OR=0.80, CI=0.74-0.86), younger age (OR=1.00, CI=0.99-1.00), several schizophrenia subtypes (paranoid: OR=1.24, CI=1.11-1.38,hebephrenic: OR=1.30, CI=1.03-1.63, other: OR=1.95 CI=1.17-3.24, unspecified: OR=1.21 CI=1.05-1.40), living alone (OR=1.12, CI=1.01-1.24), being institutionalized (OR=1.23, CI=1.06-1.42), receiving early retirement pension (OR=1.21, CI=1.10-1.34), higher Charlson Co-morbidity Index score (OR=1.13, CI=1.07-1.19), higher antipsychotic defined daily doses (OR=3.05, CI=-2.95-3.16), treatment with clozapine (OR=3.09, 95% CI=2.78-3.44), and treatment with antidepressants (OR=1.97 (CI=1.83-2.13), long-acting injectable antipsychotics (OR=1.48, CI=1.34-1.63), and anticholinergics (OR=1.74, CI=1.51-2.01). APP remains common in schizophrenia with substantial temporal and geographical variation, being associated with indicators of illness severity and chronicity.
Copyright © 2015 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Antipsychotic; FGA; Polypharmacy; SGA; Schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 26256007     DOI: 10.1016/j.euroneuro.2015.04.027

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  7 in total

Review 1.  Switching and augmentation strategies for antipsychotic medications in acute-phase schizophrenia: latest evidence and place in therapy.

Authors:  Kotaro Hatta; Naoya Sugiyama; Hiroto Ito
Journal:  Ther Adv Psychopharmacol       Date:  2018-01-29

2.  Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial.

Authors:  Adriana Foster; Peter Buckley; John Lauriello; Stephen Looney; Nina Schooler
Journal:  J Clin Psychopharmacol       Date:  2017-10       Impact factor: 3.153

3.  Medication Gaps and Antipsychotic Polypharmacy in Previously Hospitalized Schizophrenia Patients: An Electronic Cohort Study in Three Canadian Provinces.

Authors:  Evyn Peters; Arash Shamloo; Rohit J Lodhi; Gene Marcoux; Kylie Jackson; Shawn Halayka; Lloyd Balbuena
Journal:  Front Psychiatry       Date:  2022-06-15       Impact factor: 5.435

4.  Characteristics of Medicaid Recipients Receiving Persistent Antipsychotic Polypharmacy.

Authors:  Robert O Cotes; David R Goldsmith; Sarah L Kopelovich; Cathy A Lally; Benjamin G Druss
Journal:  Community Ment Health J       Date:  2017-11-10

5.  Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.

Authors:  Jari Tiihonen; Heidi Taipale; Juha Mehtälä; Pia Vattulainen; Christoph U Correll; Antti Tanskanen
Journal:  JAMA Psychiatry       Date:  2019-05-01       Impact factor: 21.596

6.  Antipsychotic polypharmacy and clozapine prescribing patterns: evolution and correlates before and after a psychiatric hospitalisation.

Authors:  Juliette Lagreula; Philippe de Timary; Laure Elens; Olivia Dalleur
Journal:  Ther Adv Psychopharmacol       Date:  2022-08-23

7.  Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN).

Authors:  Kai-Chun Yang; Yin-To Liao; Yen-Kuang Yang; Shih-Ku Lin; Chih-Sung Liang; Ya-Mei Bai
Journal:  CNS Drugs       Date:  2021-07-27       Impact factor: 5.749

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.